Radical Prostatectomy versus Observation for Localized Prostate Cancer
By Timothy J. Wilt, M. Brawer, Karen M. Jones, Michael J. Barry, W. J. Aronson, Steven Fox, Jeffrey R. Gingrich, John T. Wei, I. Nsouli, G. Snider and 3 more. New England Journal of Medicine, 2012
1,684 citations recorded by the source corpus.
BACKGROUND The effectiveness of surgery versus observation for men with localized prostate cancer detected by means of prostate-specific antigen (PSA) testing is not known. METHODS From November 1994 through January 2002, we randomly assigned 731 men with localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter) to radical prostatectomy or observation and followed them through January 2010. The primary outcome was all-cause mortality; the secondary outcome was prostate-cancer mortality. RESULTS During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation (hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P = 0.22; absolute risk reduction, 2.9 percentage points). Among men assigned to radical prostatectomy, 21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%) assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P = 0.09; absolute risk reduction, 2.6 percentage points). The effect of treatment on all-cause and prostate-cancer mortality did not differ according to age, race, coexisting conditions, self-reported performance status, or histologic features of the tumor. Radical prostatectomy was associated with reduced all-cause mortality among men with a PSA value greater than 10 ng per milliliter (P = 0.04 for interaction) and possibly among those with intermediate-risk or high-risk tumors (P = 0.07 for interaction). Adverse events within 30 days after surgery occurred in 21.4% of men, including one death. CONCLUSIONS Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer mortality, as compared with observation, through at least 12 years of follow-up. Absolute differences were less than 3 percentage points. (Funded by the Department of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials.gov number, NCT00007644.)
Subfields: Pulmonary and Respiratory Medicine, Urology
View Paper: https://www.semanticscholar.org/paper/323755ed3669e4f580eb8405ff1ed7dac18975db
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
- Jonathan I. Epstein
- Andrew J. Vickers
- Michel Bolla
- N. Mottet
- J. Bellmunt
- V. Matveev
- Steven Joniau
- Thomas Wiegel
Citations in the corpus
- A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. (2014, background): “Men with low-risk PCa defined by conventional clinical and pathologic features already have a low probability of progression to lethal disease [42,43].”
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2017, background): “An RCT was unable to show an OS and CSS difference at 10 yr between RP and WW in 731 men with screen-detected clinically organ-confined PCa [38].”
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options (2017, methodology): “In the PIVOT and ProtecT studies, 20% and 50%, respectively, of patients who started on active surveillance received treatment within 10 years.(17,18) Men with a family history of aggressive prostate cancer characterized by early metastasis may not be ideal candidates for active surveillance even wh”
- A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score (2015, background): “Analyzing some of the highest impact recent articles on PCa reveals considerable diversity of Gleason score groupings: 2–4, 5–7, 8–10 (Prostate Cancer Outcomes Study) [7]; 2–6, 7, 8–10 (Scandinavian Prostate Cancer Group Study); and 2–6, 7–10 (Prostate Cancer Prevention Trial and Prostate Cancer Int”
- EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. (2020, background): “An RCT was unable to show any survival difference at 10 yr between RP and WW in 731 men with screen-detected clinically organ-confined PCa [85].”
- Genetics and biology of prostate cancer (2018, background): “Low-risk cancers (Gleason 3 + 3) are typically managed by active surveillance, as large randomized clinical trials show no mortality differences between active surveillance and radical prostatectomy or radiotherapy (Iversen et al. 1995; Wilt et al. 2012; Bill-Axelson et al. 2014; Hamdy et al. 2016; ”